A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Lacnotuzumab (Primary)
- Indications Pigmented villonodular synovitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 08 Nov 2018 Planned End Date changed from 31 Oct 2018 to 27 Nov 2018.
- 18 Jun 2018 Planned End Date changed from 21 May 2021 to 31 Oct 2018.